Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy

被引:18
作者
Agarwal, AK
Venugopalan, P
机构
[1] Sultan Qaboos Univ, Coll Med, Dept Cardiol, Muscat, Oman
[2] Sultan Qaboos Univ Hosp, Dept Cardiol, Muscat, Oman
关键词
carvedilol; exercise; heart rate response; atrial fibrillation; heart failure;
D O I
10.1016/S1388-9842(01)00130-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fourteen digitalised patients diagnosed with heart failure (NYHA Functional class II) with idiopathic dilated cardiomyopathy in chronic established atrial fibrillation were administered carvedilol in addition to their anti-heart failure medications in an attempt to improve their heart rate control. Fourteen matched patients who did not receive carvedilol acted as control subjects. Patients treated with carvedilol showed significantly reduced resting heart rates (10-36%), maximal heart rates on exercise (5-20%) and an increased exercise time (2-30%) on treadmill stress tests (all P = 0.001). Ventricular ectopic activity was also diminished. This was associated with symptomatic improvement in effort intolerance and palpitations. NYHA functional class, left ventricular dimensions and ejection fractions did not improve during the study period of 3 months, Thus, addition of carvedilol to digoxin had a beneficial effect on exercise tolerance in patients with idiopathic dilated cardiomyopathy in atrial fibrillation by virtue of an improved heart rate control both at rest and on exercise. Carvedilol was well tolerated despite impaired myocardial function. (C) 2001 European Society of Cardiology. All rights reserved.
引用
收藏
页码:437 / 440
页数:4
相关论文
共 31 条
[1]  
Abraham WT, 1998, CIRCULATION, V98, P378
[2]  
BASHIR Y, 1993, BRIT HEART J, V70, P8
[3]   Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure [J].
Bristow, MR ;
Gilbert, EM ;
Abraham, WT ;
Adams, KF ;
Fowler, MB ;
Hershberger, RE ;
Kubo, SH ;
Narahara, KA ;
Ingersoll, H ;
Krueger, S ;
Young, S ;
Shusterman, N .
CIRCULATION, 1996, 94 (11) :2807-2816
[4]   Second- and third-generation beta-blocking drugs in chronic heart failure [J].
Bristow, MR ;
Abraham, WT ;
Yoshikawa, T ;
White, M ;
Hattler, BG ;
Crisman, TS ;
Lowes, BD ;
Robertson, AD ;
Larrabee, P ;
Gilbert, EM .
CARDIOVASCULAR DRUGS AND THERAPY, 1997, 11 (Suppl 1) :291-296
[5]  
CLELAND JG, 1998, BR J HOSP MED, V58, P493
[6]   The evidence for β blockers in heart failure -: Equals or surpasses that for angiotensin converting enzyme inhibitors [J].
Cleland, JGF ;
McGowan, J ;
Clark, A ;
Freemantle, N .
BRITISH MEDICAL JOURNAL, 1999, 318 (7187) :824-825
[7]  
Cleland JGF, 1996, EUR HEART J, V17, P1629
[8]  
Cohn J N, 1997, J Card Fail, V3, P173, DOI 10.1016/S1071-9164(97)90013-0
[9]   Prevention of heart failure [J].
Cohn, JN .
CARDIOLOGY, 1999, 92 :22-25
[10]   Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol [J].
Di Lenarda, A ;
Sabbadini, G ;
Salvatore, L ;
Sinagra, G ;
Mestroni, L ;
Pinamonti, B ;
Gregori, D ;
Ciani, F ;
Muzzi, A ;
Klugmann, S ;
Camerini, F .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (07) :1926-1934